SCHEMBL4900433

SCHEMBL4900433

CCC(=O)NC1CC(C)(C)N(O)C(C)(C)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.48
KDM4E B2RXH2 3/20 0.48
KMT2A Q03164 3/20 0.44
MAOB P27338 1/20 0.37
MTNR1A P48039 4/20 0.37
MTNR1B P49286 4/20 0.37
MAPK8 P45983 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
RECQL P46063 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12352252 0.89 GAA (0.50) GAAKDM4EKMT2AMAOBMAPK8
SCHEMBL4889822 0.86 GAA (0.46) GAAKDM4EKMT2AMAOBMTNR1A
SCHEMBL8771887 0.85 MAOB (0.37) GAAKDM4EKMT2AMAOBMTNR1A
SCHEMBL2594876 0.85 MAOB (0.49) GAAKDM4EKMT2AMAOBMTNR1A
SCHEMBL26415573 0.84 GAA (0.47) GAAKDM4EKMT2AMAOBMAPK8
SCHEMBL1933229 0.84 GAA (0.47) GAAKDM4EKMT2AMAOBMAPK8
SCHEMBL2302254 0.84 GAA (0.50) GAAKDM4EKMT2AMAOBMTNR1A
SCHEMBL316348 0.84 SMN1; SMN2 (0.48) GAAKDM4EKMT2AMAOBMAPK8
SCHEMBL1463814 0.84 GAA (0.47) GAAKDM4EKMT2AMAOBMAPK8
SCHEMBL12568166 0.84 GAA (0.47) GAAKDM4EKMT2AMAOBMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127371-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-04-27 US disclosed
WO-2021178690-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-09-10 WO disclosed
EP-3310819-B1 COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION BASF SE (DE) 2019-06-12 EP disclosed
US-10221255-B2 Composition for the immediate stopping of a free-radical polymerization BASF SE (DE) 2019-03-05 US disclosed
US-20180171035-A1 COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION BASF SE (DE) 2018-06-21 US disclosed
US-20180171035-A1 COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION BASF SE (DE) 2018-06-21 US disclosed
WO-2017031239-A1 NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-02-23 WO disclosed
WO-2016202883-A1 COMPOSITION FOR IMMEDIATELY ENDING RADICAL POLYMERIZATION BASF SE (DE) 2016-12-22 WO disclosed
US-20080064899-A1 Method For Producing Alpha, Beta-Unsaturated Carboxylic Acid KAWATO SEIICHI 2008-03-13 US disclosed
US-6710204-B2 N-OXYL COMPOUND CONTAINED IN AN EASILY POLYMERIZABLE MATERIAL CAN BE SUFFICIENTLY DECREASED AND LOSS OF EASILY POLYMERIZABLE MATERIAL (ACRYLIC OR METHACRYLIC ACIDS OR THEIR ESTERS) IS LITTLE MITSUBISHI RAYON CO., LTD. (JP) 2004-03-23 US disclosed
US-20030078425-A1 Decreasing method of N-oxyl compound MITSUBISHI RAYON CO., LTD. (JP) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221255-B2 Composition for the immediate stopping of a free-radical polymerization FASTKD5, TYK2, FASTKD1 GAA 4489/4885KDM4E 2885/4885KMT2A 1484/4885
US-20030078425-A1 Decreasing method of N-oxyl compound NOC2L, LOXL2, VCL GAA 722/4885KDM4E 2084/4885KMT2A 1897/4885
US-20230127371-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF TNNI3, TNNT2, REN GAA 2828/4885KDM4E 3219/4885KMT2A 4355/4885
US-20180171035-A1 COMPOSITION FOR THE IMMEDIATE STOPPING OF A FREE-RADICAL POLYMERIZATION FASTKD5, TYK2, FASTKD1 GAA 4489/4885KDM4E 2885/4885KMT2A 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.